Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Industry Can’t Endure Further Price Cuts for Creating Savings: LDP Health Affairs Chief
November 14, 2023
- Generic Study Group Discusses Industry Shake-Up through Consortia
November 14, 2023
- Japan Health Minister Seeks Industry Input for Detailed Discussions on Innovation Ecosystem
November 14, 2023
- Pfizer’s PARP Inhibitor, RSV Vaccine, Lilly’s IL-13 Med UP for Panel Review on Nov. 27
November 14, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Japan Looks to Bolster Drug Discovery, Earmarks 240 Million Yen in FY2023 Extra Budget
November 13, 2023
- Generic Study Group Not Bound by Year-End Goal to Compile Final Report, Explore Best Solutions: MHLW Official
November 13, 2023
- Shionogi’s Cefiderocol Selected for Pilot-Based Revenue Assurance System
November 13, 2023
- Revisit 25-Plus-Year Listing Requirement for Essential Drugs: Chuikyo Members
November 13, 2023
- MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
- Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
- MHLW Proposes NIP Inclusion of 15-Valent Pneumococcal Vaccine for Kids
November 10, 2023
- Industry Prods Careful Debate on Creating Separate Rules for Leqembi Re-Pricing
November 9, 2023
- MHLW Cautions against Hoarding Oseltamivir Dry Syrup amid Tight Stocks
November 9, 2023
- Chugai’s Fujihara, Alfresa’s Arakawa to Represent Industry at Chuikyo
November 9, 2023
- Accumulate Knowledge to Prevent Dementia, a “National Issue”: PM Advisor
November 8, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
- LDP Lawmakers Air Concerns over MOF Push for Negative Fee Revision
November 8, 2023
- Abecma Clears Japan Panel Review for 3rd Line MM Use
November 7, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…